Academic history

Arvind Dasari, MD, MS, is currently an Associate Professor in the Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston, TX. He also holds roles on the INTERCEPT Minimal Residual Disease Program Steering Committee and the Advisory Board & Review Committee for the MD Anderson Colorectal Moonshot.

He initially earned an MBBS degree in Internal Medicine from NTR University of Health Sciences, Hyderabad, India, in 2002 and an MS in Human Genetics from the University of Pittsburgh, Pittsburg, PA. Upon completing his Clinical Internship and Residency in Internal Medicine at the University of Pittsburgh, Pittsburgh, PA, Dr Dasari earned Clinical Fellowships in Drug Development and Medical Oncology.

Speaking on clinical research in gastrointestinal cancers

Dr Dasari has actively contributed to advancing the field of medical oncology through his involvement in various clinical research initiatives. His research interests include exploring novel treatment strategies and understanding mechanisms of resistance in cancer therapy. Notably, he has participated in the FRESCO-2 trial, which investigated new treatment options for patients with advanced colorectal cancer. Additionally, his work includes studying the genetic and molecular changes in circulating tumor DNA (ctDNA) of patients with colorectal cancer who do not respond to anti-EGFR therapies. This research aims to uncover patterns of clonal evolution and resistance, providing insights that could lead to more effective treatment approaches.